Figure 5.

miR-19b regulates the TGF-β pathway by targeting CCL1. (A) Potential binding sites between miR-19b and CCL1. (B) RT-qPCR was conducted to determine CCL1 expression in HaCaT cells treated with different concentrations of H₂O₂ (one-way ANOVA, *P < 0.05 or **P < 0.01 vs 0 µM). (C) RT-qPCR was carried out to measure the transfection efficiency of miR-19b mimic (unpaired t test, *P < 0.05). (D) Dual-luciferase reporter gene assay was performed to evaluate the effect of miR-19b mimic on the luciferase activity of WT-CCL1 or MT-CCL1 (two-way ANOVA, *P < 0.05). (E) RIP assay was used to measure the enrichment of miR-19b and CCL1 (two-way ANOVA, *P < 0.05). (F) RT-qPCR was implemented to measure the effect of miR-19b mimic and LV-CCL1 on CCL1 expression (one-way ANOVA, *P < 0.05 vs the NC mimic group; #P < 0.05 vs the miR-19b mimic + LV-NC group). (G) Western blot assay was implemented to measure the effect of miR-19b mimic and LV-CCL1 on TGF-β pathway (one-way ANOVA, *P < 0.05 vs the NC mimic group; #P < 0.05 vs the miR-19b mimic + LV-NC group).